An Open-Label Study To Determine Safety, Tolerability And Efficacy Of Long -Term Oral Lacosamide (LCM) As Adjunctive Therapy In Children With Epilepsy

Trial Profile

An Open-Label Study To Determine Safety, Tolerability And Efficacy Of Long -Term Oral Lacosamide (LCM) As Adjunctive Therapy In Children With Epilepsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2018

At a glance

  • Drugs Lacosamide (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 14 Feb 2018 This trial has been completed in Italy.
    • 08 Feb 2018 Planned End Date changed from 1 May 2022 to 1 Jul 2022.
    • 08 Feb 2018 Planned primary completion date changed from 1 May 2022 to 1 Jun 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top